Top biotech stocks to watch in second half of 2026, says Clear Street
Clear Street names five biotech stocks for 2H 2026 catalysts: MoonLake (MLTX) Buy, $70 target; Cullinan (CGEM) Buy, $46; Zura Bio (ZURA) Buy, $18; Arrivent (AVBP) Buy, $47; Protagonist (PTGX) Buy, $116. It cites planned clinical readouts and regulatory milestones, plus MLTX’s ~$200M offering and AVBP’s up to $250M ATM filing.
How this was made
The 30-second read
Why it matters
The text is mainly a catalyst roadmap with analyst ratings/price targets and a few discrete company updates (e.g., enrollment completion, FDA orphan designation, ATM filing). It is not a single-company breaking event; it supports event-driven positioning but offers limited new primary information.
Market read
Useful for building a 2H26 biotech catalyst watchlist, but it is not a fresh, single-name disclosure that would force immediate repricing today.
What to watch
The article provides expected dates and analyst targets but little on trial design details, endpoints, or probability-weighting; traders may need to reassess risk using latest protocol/endpoint specifics and financing overhangs.
Background
Clear Street compiled five high-conviction biotech names for material upside in the second half of 2026, spanning autoimmune, oncology, and rare diseases.
Ticker impact
Clear Street highlights MoonLake Immunotherapeutics’ hidradenitis suppurativa catalysts, including a Q3 2026 BLA submission and July-end psoriatic arthritis data.
Bias toward volatility and upside skew into the July-end and Q3 2026 milestones, with pullbacks possible on any trial/data disappointments.
The article provides specific timing for key readouts (July-end, Q3 BLA) plus mention of recent financing and analyst target changes, which typically amplifies event-driven repricing.
Clear Street cites Cullinan Therapeutics’ CLN-978 CD19xCD3 program with rheumatoid arthritis data expected in Q3 2026 and SLE/Sjogren’s in Q4 2026.
Potential upward drift into Q3/Q4 2026 data windows, with sharp moves around any efficacy/safety signals.
The text ties discrete future catalysts to specific indications and also notes FDA orphan drug designation, supporting a constructive risk/reward narrative.
Clear Street points to Zura Bio’s Phase 2 TibuSHIELD enrollment completion and expects 4Q26 data that triggers Lilly’s right of first negotiation.
Upside bias into 4Q26 as investors price the negotiation trigger, with downside risk if interim expectations are not met.
The article includes a concrete operational milestone (enrollment completed) and a specific downstream contractual trigger tied to 4Q26 data.
Clear Street highlights Arrivent Biopharma’s mid-2026 Phase 3 data for firmonertinib as potentially the first approved first-line EGFR exon20ins TKI in NSCLC.
High volatility with upside skew around mid-2026 Phase 3 readouts; dilution risk may cap rallies.
The article pairs a specific clinical-data timing thesis with a disclosed at-the-market equity offering program, which can affect near-term sentiment and float.
Clear Street cites Protagonist Therapeutics’ Phase 3 psoriatic arthritis readout in 2H26 and expected rusfertide approval in August 2026 as key catalysts.
Likely catalyst-driven upside/volatility into 2H26, with potential sentiment swings around the August 2026 approval backdrop.
The piece is a multi-stock watchlist and does not provide new primary trial/regulatory datapoints beyond the stated expected timing and analyst commentary.
Market effects
Reinforces a biotech “event calendar” trade theme (clinical readouts and regulatory milestones) across autoimmune and oncology programs.
Primarily US-listed biotech sentiment; no explicit cross-region macro linkage provided.
Limited—focuses on company-specific clinical timelines rather than global policy or supply-chain shocks.
Counterpoint
Watchlist-style catalyst calendars can overstate probability; dilution (e.g., ATM) and binary trial outcomes can produce sharp downside even when timelines look favorable.
Key entities
- companyMoonLake Immunotherapeutics
BLA submission expected in Q3 2026; July-end psoriatic arthritis data cited as a confidence driver.
- companyCullinan Therapeutics
CLN-978 autoimmune program data timing (Q3/Q4 2026) and FDA orphan drug designation for CLN-049 mentioned.
- companyZura Bio
Phase 2 TibuSHIELD enrollment completed; 4Q26 data tied to Lilly right of first negotiation.
- companyArrivent Biopharma
Mid-2026 Phase 3 data for firmonertinib framed as potentially first-line EGFR exon20ins TKI; ATM offering filed.
- companyProtagonist Therapeutics
Phase 3 psoriatic arthritis readout expected in 2H26; rusfertide approval expected in August 2026 referenced.
